311) today, there is no universal dengue fever treatment or vaccines unreservedly recomme |
312) f factors that are associated with poorer treatment outcome and inform the developme |
313) atment levels of perceived life stress on treatment outcome in a sample of 200 indiv |
314) ing blood is a significant factor for the treatment outcome in patients with locally |
315) udies published to date and difference in treatment protocols for TF-CBT used with p |
316) Development of treatment protocols specific to children w |
317) and caring and also on the use of medical treatment protocols. |
318) are an effective alternative to inpatient treatment that lead to sustained improveme |
319) For high-risk patients, the treatment that minimizes the risk of relap |
320) sent the hope for a new direction for HIV treatment that reduces adherence barriers |
321) Little is known about how the amount of treatment a person with aphasia receives i |
322) g signals for iron at 4 and 12 days after treatment, a significant decrease in peak |
323) physiology, pathophysiology, and disease treatment as they relate to gynecologic ma |
324) mbiont-free strain obtained by antibiotic treatment as well as genome analyses revea |
325) rofile followed by 2 weeks of either Epi treatment at 1 mg/kg/day by gavage (n = |
326) veloped for evaluating only one candidate treatment at a time, and are thus not opti |
327) he Bayesian posterior probability of each treatment being optimal. |
328) HNC) are diagnosed worldwide with primary treatment being surgery and radiotherapy. |
329) The average difference in post-treatment compared to pre-treatment non-HD |
330) high Drug Burden Index (DBI) polypharmacy treatment compared to control on physical |
331) on administration, hygiene and isolation, treatment decisions, or invasive procedure |
332) To improve dengue triage and treatment decisions, the WHO recommends cl |
333) aying reward responsiveness to accelerate treatment development for neuropsychiatric |
334) ions and laboratory animals, which hamper treatment development. |
335) Moreover, statin treatment did not reduce the number of flo |
336) Importantly, statin treatment did not reverse d-flow-regulated |
337) Treatment dose (amount of treatment) has b |
338) or post-stroke aphasia and to explore how treatment dose is conceptualized, measured |
339) approach to alleviate liver fibrosis, and treatment efficacy can be monitored by obs |
340) ould very likely be necessary to maintain treatment efficacy. |
341) The use of specific clinical treatment goals (e.g., two-hour pain free |
342) iol doses ≥ 1.5 mcg/day to meet current treatment goals. |
343) ificant main effect in the high vitamin D treatment group in VDAART. |
|